Clinical Trials
21 trialsNCT05800574 2026-05-22
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT07195734 2026-05-19
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05172245 2026-05-18
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06234748 2026-05-18
ARTHOUSE
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT06702033 2026-05-15
MINT-2
Washington University School of Medicine
Phase 2 Recruiting
NCT03811015 2026-05-13
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05063552 2026-05-13
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05541016 2026-05-12
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Mayo Clinic
Phase 2 Recruiting
NCT06445114 2026-05-08
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT04116047 2026-05-07
CompARE
University of Birmingham
Phase 3 Active not recruiting
NCT05050162 2026-05-07
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NRG Oncology
Phase 2/3 Suspended
NCT05721755 2026-05-05
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT03952585 2026-05-04
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT06532279 2026-05-04
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NCT06223568 2026-04-28
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06706401 2026-04-24
LYSARI
Centre Leon Berard
Phase 3 Recruiting
NCT05491512 2026-04-23
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07209189 2026-04-23
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05075980 2026-04-13
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
Phase 2 Active not recruiting
NCT01898494 2026-04-01
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06323460 2026-03-24
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting